MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Development of therapeutic substances for the disassembly of α-synuclein aggregates as disease-modifying treatment of synucleinopathies

A. Willuweit, M. Sevenich, G. Tamgüney, J. Mohrlüder, D. Willbold (Düsseldorf, Germany)

Meeting: 2023 International Congress

Abstract Number: 1362

Keywords: Alpha-synuclein, Disease-modifying strategies, Parkinson’s

Category: Parkinson’s Disease: Pharmacology and Therapy

Objective: Development of high-affinity ligands to α-synuclein (α-syn) for a therapeutic approach aiming for the disassembly of α-syn aggregates as a disease-modifying treatment of synucleinopathies.

Background: Parkinson’s disease (PD) is the most common neurodegenerative movement disorder worldwide and the most prevalent α-synucleinopathy. Multiple lines of evidence indicate that oligomeric α-syn assemblies play a key role in prion-like cell-to-cell transmission and induction of toxicity, leading to neurodegeneration in PD. Consequently, disassembly of these prion-like aggregates into physiological α-syn monomers is a very efficient way to interfere with disease progression in PD and other synucleinopathies.

Method: We have performed a mirror-image phage display against full-length α-syn and selected all-D-enantiomeric peptide ligands by means of of next generation sequencing. The efficacy of the compounds was characterized usingsurface plasmon resonance, atomic forced microscopy (AFM), dynamic light scattering (DLS), size exclusion chromatography (SEC), paramagnetic relaxation enhancement, nuclear magnetic resonance (NMR) spectroscopy, Thioflavin-T aggregation assay, cell-viability and cellular aggregation assays.

Results: We identified two lead compounds, SVD-1 and SVD-1a, which inhibited de novo and seeded α-syn aggregation very efficiently. Both showed high affinity to α-syn in the picomolar KD range and the interaction with α-syn was further characterized by NMR analyses. SVD-1a reduced toxic effects and intracellular seeding capacity of preformed α-syn oligomers in cell culture. Furthermore, we can show the compound´s ability to specifically disassemble α-syn oligomers into monomers as demonstrated by AFM, time dependent DLS and SEC analyses.

Conclusion: The present work reports on a promising lead compound capable of destabilizing and disassembling α-syn aggregates as a new disease-modifying treatment strategy against Parkinson’s disease and other synucleinopathies.

This abstract has been submitted to the AD/PD 2023 conference and will be presented on 03/31/2023.

To cite this abstract in AMA style:

A. Willuweit, M. Sevenich, G. Tamgüney, J. Mohrlüder, D. Willbold. Development of therapeutic substances for the disassembly of α-synuclein aggregates as disease-modifying treatment of synucleinopathies [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/development-of-therapeutic-substances-for-the-disassembly-of-%ce%b1-synuclein-aggregates-as-disease-modifying-treatment-of-synucleinopathies/. Accessed May 24, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/development-of-therapeutic-substances-for-the-disassembly-of-%ce%b1-synuclein-aggregates-as-disease-modifying-treatment-of-synucleinopathies/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley